Editas Medicine is a leading gene editing company focused on developing CRISPR medicines for people with serious diseases.

Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). Both nucleases have distinct gene editing and targeting capabilities.

Editas Medicine is a pioneering gene editing company focused on developing transformative medicines, translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for …

Editas Medicine is a leading gene editing company dedicated to developing a robust pipeline of medicines to treat people living with serious diseases around the world. We have built a platform that utilizes CRISPR gene editing, a revolutionary approach to developing medicines.

Nov 4, 2024 · Access the latest press releases and other information from Editas Medicine, a leading gene editing company dedicated to developing CRISPR medicines for people living with serious diseases around the world.

Get in touch with Editas Medicine, a leading gene editing company dedicated to developing CRISPR-based medicines for people living with serious diseases around the world.

Oct 18, 2023 · Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.

Editas Medicine is a Leader in the CRISPR-based Gene Editing Medicine Field • Reni-cel is an investigational gene editing medicine that is a potential “best in class” treatment for sickle cell disease and beta thalassemia • Ongoing RUBY and EdiTHAL clinical trials • Proprietary AsCas12a is a high fidelity and high efficiency CRISPR ...

CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced positive initial clinical data from the ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101.

Editas Medicine is building a leading gene editing company that uses CRISPR to develop medicines for people living with serious diseases. Learn more about Editas Medicine, our Inspiritas Culture, and how to join our team.